Âé¶¹ÒùÔº

July 11, 2022

Breakthrough in study of how epithelial cells become cancerous

CDCP1 induces basal delamination through Src activation within lipid rafts. (A) Schematic model of CDCP1 and its mutants. Blue squares indicate lipid raft domains, and asterisks indicate point mutations. (B and C) MDCK type I cells harboring CDCP1-EGFP, CDCP1-YF-EGFP, CDCP1-CG-EGFP, or CDCP1-PR-EGFP were mixed with wild-type cells at a ratio of 35:1 and incubated with Dox for 24 h. Cell behavior was assessed using the criteria defined in Figure 1C, and representative results were shown. The mean ratios ± SDs were obtained from three independent experiments. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; two-way ANOVA was calculated compared with the control cells. (D and E) Type I cells harboring CDCP1-EGFP, CDCP1-YF-EGFP, CDCP1-CG-EGFP, or CDCP1-PR-EGFP were mixed with wild-type cells at a ratio of 8:1, the mosaic cysts were grown in collagen matrix in the presence of Dox for 2 days. Cell behavior was monitored (n > 100) and assessed by using criteria for the three states, and representative results were shown. The mean ratios ± SDs were obtained from three independent experiments. ∗p < 0.05; ∗∗∗p < 0.001; two-way ANOVA was calculated compared with the control mosaic cysts. (B and D) The scale bars indicate 50 μm. Credit: Current Biology (2022). DOI: 10.1016/j.cub.2022.06.038
× close
CDCP1 induces basal delamination through Src activation within lipid rafts. (A) Schematic model of CDCP1 and its mutants. Blue squares indicate lipid raft domains, and asterisks indicate point mutations. (B and C) MDCK type I cells harboring CDCP1-EGFP, CDCP1-YF-EGFP, CDCP1-CG-EGFP, or CDCP1-PR-EGFP were mixed with wild-type cells at a ratio of 35:1 and incubated with Dox for 24 h. Cell behavior was assessed using the criteria defined in Figure 1C, and representative results were shown. The mean ratios ± SDs were obtained from three independent experiments. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; two-way ANOVA was calculated compared with the control cells. (D and E) Type I cells harboring CDCP1-EGFP, CDCP1-YF-EGFP, CDCP1-CG-EGFP, or CDCP1-PR-EGFP were mixed with wild-type cells at a ratio of 8:1, the mosaic cysts were grown in collagen matrix in the presence of Dox for 2 days. Cell behavior was monitored (n > 100) and assessed by using criteria for the three states, and representative results were shown. The mean ratios ± SDs were obtained from three independent experiments. ∗p < 0.05; ∗∗∗p < 0.001; two-way ANOVA was calculated compared with the control mosaic cysts. (B and D) The scale bars indicate 50 μm. Credit: Current Biology (2022). DOI: 10.1016/j.cub.2022.06.038

Epithelial cells, which line the surfaces and organs of the body, can protect themselves against cancer by removing unhealthy or abnormal cells through a mechanism known as "apical extrusion," where the damaged cells are forcibly removed from the cell layer by the surrounding healthy cells. The underlying process by which the defenses of apical extrusion are overcome, allowing cells to become invasive and cancerous, has remained unknown. Now, however, a group from Osaka University have identified that a molecule called Src is key in this process.

Src is a key regulator of fundamental cell processes such as cell migration and adhesion. It is known to be encoded by an oncogene, a gene with the potential to cause cancer, because the abnormal activation or increased expression of Src has already been linked to various types of cancer. It is thought to play a key role in cancer progression but the mechanistic switch from its normal role to a cancerous one has remained unknown.

The cell membrane, surrounding the cell, contains dynamic arrangements of various molecules, including lipids. These can assemble into more ordered areas known as "lipid rafts." The team compared contrasting phenotypes of different cells that were transformed by Src, and showed that the location of Src within the determined how it acted. When Src was located inside a lipid raft, were able to become invasive and overcome the protective mechanisms of the normal cell layer.

But how is the location of Src controlled? They showed that another molecule, known as CDCP1, forms a molecular scaffold that activates Src. "By analyzing cancer cells, we showed that CDCP1 promoted cancer cell invasion," explains lead author Kentaro Kajiwara, "while inhibition of CDCP1 led to the elimination of the cancerous cells by apical extrusion."

CDCP1 recruitment of Src to lipid rafts triggers a cascade that ultimately results in cancer cells escaping the fate of apical extrusion by invading the basal layer, but that initial recruitment step is vital in this process. "The spatial control of Src activation by CDCP1 in lipid rafts is vital to convey resistance to the process of apical extrusion and allows the cancerous cells to become invasive, promoting carcinogenesis," explains senior author Masato Okada.

The expression of CDCP1 is already known to be increased in certain types of cancers, such as lung and pancreatic cancer and this work provides mechanistic insight into its roles in cancer cell invasion. This study shows that CDCP1 could be a promising target of drug treatment for early-stage cancers.

The article, "Src activation in confers with invasive potential to escape from apical extrusion during cell competition," was published in Current Biology.

Get free science updates with Science X Daily and Weekly Newsletters — to customize your preferences!

More information: Kentaro Kajiwara et al, Src activation in lipid rafts confers epithelial cells with invasive potential to escape from apical extrusion during cell competition, Current Biology (2022).

Journal information: Current Biology

Provided by Osaka University

Load comments (0)

This article has been reviewed according to Science X's and . have highlighted the following attributes while ensuring the content's credibility:

Get Instant Summarized Text (GIST)

This summary was automatically generated using LLM.